NCT03154086 2019-08-09
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
GlaxoSmithKline
Phase 1 Completed
GlaxoSmithKline
King Fahad Medical City